Creo Medical Group (LSE:CREO) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:CREO Creo Medical Group PLC LSE:CREO
52 GF Score
Price £0.14
GF Value £0.18
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Creo Medical Group Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

LSE:CREO
52GF Score
Creo Medical Group PLC LSE:CREO
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Creo Medical Group (LSE:CREO) Overvalued in 2026?

Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued. The current stock price of £0.14 is trading 20.8% below its estimated GF Value™ of £0.18. GuruFocus considers Creo Medical Group to be Modestly Undervalued.

Key valuation signals for LSE:CREO:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: £0.18 vs. price of £0.14 (20.8% below fair value)
  • GF Score™: 52/100 with 6 warning signs

No single metric tells the full story. See the LSE:CREO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Creo Medical Group Business Description

Address Beaufort Park Way, Unit 2, Creo House, Beaufort Park, Chepstow, GBR, NP16 5UH
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
52GF Score

Get the complete analysis for LSE:CREO

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.14
Price
£0.18
GF Value